Figure 1
Figure 1. Effect of IVIg on the generation and activation of OVA-specific T cells. (A) Groups of 4 mice were immunized with OVA and treated or not with IVIg, as described in “OVA immunization and antigenic recall.” Spleens were recovered after 28 days, and the splenocytes (10 × 106 cells/mL for the secretion of IFN-γ and IL-4 and 5 × 106 cells/mL for IL-10) were stimulated in vitro with OVA-IC. After 3 days, the presence of OVA-specific T cells was evaluated by measuring the secretion of IFN-γ, IL-4, and IL-10 using ELISA. (B) Groups of 4 mice were immunized with OVA in the absence of IVIg. Spleens were recovered after 28 days, and the splenocytes were stimulated in vitro for 3 days with OVA-ICs, in the presence or not of 10 mg/mL IVIg. OVA-specific T-cell activation was evaluated by measuring cytokine secretion by ELISA. The results are representative of 2 independent experiments. *P < .001.

Effect of IVIg on the generation and activation of OVA-specific T cells. (A) Groups of 4 mice were immunized with OVA and treated or not with IVIg, as described in “OVA immunization and antigenic recall.” Spleens were recovered after 28 days, and the splenocytes (10 × 106 cells/mL for the secretion of IFN-γ and IL-4 and 5 × 106 cells/mL for IL-10) were stimulated in vitro with OVA-IC. After 3 days, the presence of OVA-specific T cells was evaluated by measuring the secretion of IFN-γ, IL-4, and IL-10 using ELISA. (B) Groups of 4 mice were immunized with OVA in the absence of IVIg. Spleens were recovered after 28 days, and the splenocytes were stimulated in vitro for 3 days with OVA-ICs, in the presence or not of 10 mg/mL IVIg. OVA-specific T-cell activation was evaluated by measuring cytokine secretion by ELISA. The results are representative of 2 independent experiments. *P < .001.

Close Modal

or Create an Account

Close Modal
Close Modal